期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

联合多西紫杉醇治疗非激素依赖性前列腺癌临床进展 被引量：5

Update of Combined Therapies with Docetaxel for Hormone-independent Prostate Cancer
下载PDF
导出
摘要 非激素依赖性前列腺癌（HIPC）是PCa发展的终末阶段，它的中位生存时间短，约9-18个月。两个大的Ⅲ期临床实验证实多西紫杉醇化疗能延长HIPC患者的生存期。新的联合治疗策略已经发展，结果很有前景，目前大多数研究均集中在联合多西紫杉醇和化疗药物（骨钙三醇）、抗血管生成药、疫苗、生物制剂等上。本文对联合多西紫杉醇治疗HIPC的新进展作一综述。 Hormone-independent prostate cancer （HIPC） is the end stage of prostate cancer, with a short median survival of 9-18 months for the patients. Two large phase Ⅲ studies have demonstrated a survival advantage of docetaxel chemotherapy in HIPC patients. New combined protocols have been developed with promising results. These protocols propose a combination with docetaxel, chemotherapy, antiangiogenic agents, vaccine and biological drugs. This review focuses the progress achieved the combined therapies for HIPC.
作者 李天庆 王剑松
机构地区 昆明医学院第二附属医院泌尿外科
出处 《中华男科学杂志》 CAS CSCD 2008年第3期264-267,共4页 National Journal of Andrology
关键词 前列腺肿瘤 多西紫杉醇 治疗 prostate cancer docetaxel therapy
分类号 R737.25 [医药卫生—肿瘤]
  • 相关文献

参考文献23

  • 1Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer [J]. N Engl J Med, 2004, 351(15):1502-1512.
  • 2Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxan-trone and prednisone for advanced refractory prostate cancer[J]. N Engl J Med, 2004, 351 (15) :1513-1520.
  • 3Kraus LA, Samuel SK, Sehmid SM, et al. The mechanism of action of doeetaxel (Taxotere) in xenograft models is not limited to bel-2 phosphorylation [ J]. Invest New Drugs, 2003, 21 ( 3 ) : 259-268.
  • 4Beer TM, Eilers KM, Garzotto M, et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer[ J]. J Clin Oncol, 2003, 21 (1) :123-128.
  • 5Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitfiol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators[J]. J Clin Oncol, 2007, 25 ( 6 ) : 669 -674.
  • 6Petrioli R, Paolelli L, Franeini E, et al. Weekly docetaxel and epirubicin in treatment of advanced honneone-refractory prostate cancer[J]. Urology, 2007, 69( 1 ):142-146.
  • 7Vordos D, Panic B, Vacherot F, et al. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer [J]. BJU Int, 2004, 94(4) :524 -527.
  • 8Bertelli G, Heouaine A, Arena G, et al. Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients[ J]. Cancer Chemother Pharmacol, 2006, 57( 1 ) :46- 51.
  • 9Berry W, Friedland D, Fleagle J. A phase Ⅱ study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer[J]. Clin Genitourin Cancer, 2006, 5(2) : 131-137.
  • 10XU Feng WANG Jin SHEN Yali ZHANG Hong ZHOU Qinghua.Phase Ⅰ/Ⅱ study of gemcitabine and oxaliplatin chemotherapy in combination with concurrent 3-D conformal radiotherapy for locally advanced non-small cell lung cancer[J].中国肺癌杂志,2006,9(4):362-368. 被引量：6

二级参考文献21

  • 1Liao M. Some features of lung cancer in China. Lung Cancer,1993,10(1-2) : 107 116.
  • 2Johnson DH, Einhorn LH, Bartolucci A, et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced,unresectable non-small cell lung cancer. Ann Intern Med, 1990,113(1) : 33-38.
  • 3Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer, 1987, 59(11):1874-1881.
  • 4Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ,1995,311(7010):899-909.
  • 5Byhardt RW, Scott C, Sause WT, et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys,1998,42(3) : 469-478.
  • 6Furuse K, Fukuoka M, Takada H, et al. Phase Ⅲ study of concurrent versus sequential thoracic radiotherapy in combination with mitomycine, vindesine and cisplatin in unresectable stage Ⅲ non-small-cell lung cancer: five-year median follow-up results. Proc Am Soc Clin Oncol,1999,18 : 458.
  • 7Soto Parra H, Cavina R, Latteri F, et al. Three-week versus fourweek schedule of cisplatin and gemcitabine: resuhs-of a randomized phase Ⅱ study. Ann Oncol,2002,13(7):1080-1086.
  • 8Abratt RP, Bezwoda WR, Falkson G, et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase Ⅱ study. J Clin Oncol,1994,12(8) : 1535-1540.
  • 9Langer CJ. The role of new agents in advanced non-small-cell lung carcinoma. Curr Oncol Rep,2000,2(1) : 76-89.
  • 10Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res, 1998,4(5) : 1087-1100.

共引文献5

同被引文献46

引证文献5

二级引证文献11

中华男科学杂志
2008年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部